{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-032926","form_type":"8-K","ticker":"CING","cik":"0001862150","company_name":"Cingulate Inc.","filed_at":"2024-08-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.996736+00:00","generated_at":"2026-05-31T08:43:29.708771+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cingulate increases ATM offering capacity by $2.86M; receives European patent for ADHD drug CTx-1301","bullets":["Increased maximum aggregate offering of common stock under Sales Agreement from $8.47M to $11.33M; filed prospectus supplement for $2.86M in additional shares.","Previously sold $8.47M of common stock under the Sales Agreement with H.C. Wainwright & Co.","European patent (EP 3261625) granted for lead asset CTx-1301 (dexmethylphenidate) for ADHD on August 14, 2024.","Patent covers up to 30 European territories, including the United Kingdom."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-032926","json":"https://secwatch.observer/filing/0001493152-24-032926.json","markdown":"https://secwatch.observer/filing/0001493152-24-032926.md","text":"https://secwatch.observer/filing/0001493152-24-032926.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1862150/000149315224032926/0001493152-24-032926-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1862150/000149315224032926/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:43:29.708771+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}